Boehringer Ingelheim and Sanofi Enter into Alliance
News Jan 22, 2015
Boehringer Ingelheim and Sanofi have announced that they enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies.
Boehringer Ingelheim’s cell culture operations will provide contract manufacturing capacities to support the production of Sanofi’s biologics pipeline.
Under the terms of the agreement Sanofi will have access to Boehringer Ingelheim’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply. Initial product transfers will begin in early 2015.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019